Steven D Nathan

List of Publications by Year
in descending order

273 papers	15,415 citations	26567 56 h-index	19136 118 g-index
293 all docs	293 docs citations	293 times ranked	10849 citing authors

#	Article	IF	Citations
1	A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2083-2092.	13.9	2,959
2	International Guidelines for the Selection of Lung Transplant Candidates: 2006 Updateâ€"A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 745-755.	0.3	1,080
3	Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis. Chest, 2006, 129, 746-752.	0.4	741
4	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
5	Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal, 2019, 53, 1801914.	3.1	428
6	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal, 2016, 47, 243-253.	3.1	349
7	Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium. Chest, 2011, 140, 221-229.	0.4	296
8	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. New England Journal of Medicine, 2021, 384, 325-334.	13.9	292
9	Lactic Acid Is Elevated in Idiopathic Pulmonary Fibrosis and Induces Myofibroblast Differentiation via pH-Dependent Activation of Transforming Growth Factor-Î². American Journal of Respiratory and Critical Care Medicine, 2012, 186, 740-751.	2.5	265
10	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 33-41.	5.2	240
11	Pulmonary Hypertension and Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis. Chest, 2007, 131, 657-663.	0.4	228
12	Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine, 2008, 102, 1305-1310.	1.3	197
13	Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 875-880.	2.5	195
14	Serial Development of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2008, 76, 288-294.	1.2	193
15	Benefits of Intensive Treadmill Exercise Training on Cardiorespiratory Function and Quality of Life in Patients With Pulmonary Hypertension. Chest, 2013, 143, 333-343.	0.4	172
16	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170057.	3.0	162
17	Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respiratory Medicine, 2010, 104, 1035-1041.	1.3	161
18	Treatment of Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2009, 135, 1455-1461.	0.4	153

#	Article	IF	Citations
19	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	2.7	151
20	Prediction of Minimal Pressure Support During Weaning From Mechanical Ventilation. Chest, 1993, 103, 1215-1219.	0.4	142
21	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine,the, 2019, 7, 780-790.	5.2	139
22	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respiratory Medicine,the, 2017, 5, 72-84.	5.2	137
23	Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. European Respiratory Journal, 2016, 48, 843-851.	3.1	134
24	All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 825-831.	2.5	130
25	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
26	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
27	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respiratory Medicine,the, 2019, 7, 487-496.	5.2	119
28	High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. Respiratory Care, 2021, 66, 909-919.	0.8	119
29	Outcomes for Patients With Sarcoidosis Awaiting Lung Transplantation. Chest, 2002, 122, 233-238.	0.4	114
30	Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3958-3963.	3.3	113
31	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respiratory Medicine,the, 2015, 3, 473-482.	5.2	112
32	Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1200-1207.	2.5	101
33	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research, 2016, 3, e000105.	1.2	96
34	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
35	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 712-715.	2.5	92
36	Lung Size Mismatch in Bilateral Lung Transplantation Is Associated With Allograft Function and Bronchiolitis Obliterans Syndrome. Chest, 2012, 141, 451-460.	0.4	91

#	Article	IF	Citations
37	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
38	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight, 2021, 6, .	2.3	86
39	Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 914-922.	1.3	85
40	Work of Breathing After Extubation. Chest, 1995, 107, 204-209.	0.4	84
41	Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine, 2019, 40, 541-553.	2.7	83
42	Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. European Respiratory Journal, 2012, 39, 1520-1533.	3.1	82
43	Heart rate recovery after sixâ€minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology, 2011, 16, 439-445.	1.3	80
44	Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 1159-1164.	0.3	76
45	Pulmonary Embolism in Idiopathic Pulmonary Fibrosis Transplant Recipients. Chest, 2003, 123, 1758-1763.	0.4	75
46	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2014, 108, 1626-1632.	1.3	75
47	Outcomes After Hospitalization in Idiopathic Pulmonary Fibrosis. Chest, 2015, 147, 173-179.	0.4	72
48	Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis. Chest, 2008, 133, 640-645.	0.4	71
49	Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics, 2010, 96, 134-145.	1.3	70
50	Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 1165-1171.	0.3	69
51	Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. Journal of Heart and Lung Transplantation, 2018, 37, 925-932.	0.3	69
52	Lung Transplantation. Chest, 2005, 127, 1006-1016.	0.4	67
53	The Diagnosis and Management of AirwayÂComplications Following LungÂTransplantation. Chest, 2017, 152, 627-638.	0.4	67
54	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. European Respiratory Journal, 2020, 55, 1901747.	3.1	67

#	Article	IF	Citations
55	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. PLoS ONE, 2020, 15, e0242651.	1.1	67
56	Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S17-S24.	0.5	65
57	Sarcoidosis, Race, and Short-term Outcomes Following Lung Transplantation. Chest, 2004, 125, 990-996.	0.4	63
58	A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk ofÂPulmonary Hypertension Associated With Pulmonary Fibrosis. Chest, 2020, 158, 637-645.	0.4	62
59	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respiratory Medicine,the, 2021, 9, 1266-1274.	5.2	62
60	Pulmonary Hypertension in Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 703-714.	0.8	61
61	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
62	IPF clinical trial design and endpoints. Current Opinion in Pulmonary Medicine, 2014, 20, 463-471.	1.2	58
63	Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 167.	0.8	57
64	Bronchiolitis Obliterans in Single-Lung Transplant Recipients. Chest, 1995, 107, 967-972.	0.4	56
65	Aspergillus and Endobronchial Abnormalities in Lung Transplant Recipients. Chest, 2000, 118, 403-407.	0.4	56
66	Pulmonary Complications of Lung Transplantation. Chest, 2011, 139, 402-411.	0.4	55
67	Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 211-220.	2.5	55
68	The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2018, 15, 3-10.	1.5	54
69	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration, 2018, 96, 514-524.	1.2	54
70	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine, 2019, 153, 44-51.	1.3	54
71	Lung Transplantation for Patients With COVID-19. Chest, 2022, 161, 169-178.	0.4	54
72	The Red Cell Distribution Width as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis. Chest, 2013, 143, 1692-1698.	0.4	52

#	Article	IF	Citations
73	The HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2011, 6, e14715.	1.1	51
74	The Influence of Alternative Instruction on 6-Min Walk Test Distance. Chest, 2013, 144, 1900-1905.	0.4	49
75	Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1445-1451.	3.1	49
76	Native Lung Complications in Single-lung Transplant Recipients and the Role of Pneumonectomy. Journal of Heart and Lung Transplantation, 2009, 28, 851-856.	0.3	48
77	Glucose Transporter-1 Distribution in Fibrotic Lung Disease. Chest, 2013, 143, 1685-1691.	0.4	47
78	Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest, 2003, 124, 922-8.	0.4	46
79	Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts. American Journal of Pathology, 2015, 185, 943-957.	1.9	43
80	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2021, 325, 1841.	3.8	43
81	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Current Opinion in Pulmonary Medicine, 2013, 19, 466-473.	1.2	42
82	Dysregulation of Galectin-3. Implications for Hermansky-Pudlak Syndrome Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 605-613.	1.4	42
83	Singleâ€center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transplant Infectious Disease, 2019, 21, e13166.	0.7	40
84	Pulmonary Hypertension due to Lung Disease and/or Hypoxia. Clinics in Chest Medicine, 2013, 34, 695-705.	0.8	39
85	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 479-489.	1.2	38
86	The Future of Lung Transplantation. Chest, 2015, 147, 309-316.	0.4	37
87	Dynamic Patient Counseling. Chest, 2012, 142, 1005-1010.	0.4	36
88	Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient. Chest, 2015, 148, 242-252.	0.4	36
89	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 196-201.	0.4	35
90	Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respiratory Research, 2018, 5, e000323.	1.2	35

#	Article	IF	Citations
91	The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis. Respirology, 2011, 16, 481-486.	1.3	34
92	Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. Journal of Heart and Lung Transplantation, 2021, 40, 822-830.	0.3	34
93	Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clinical Infectious Diseases, 2022, 75, e491-e498.	2.9	34
94	Outcomes of COPD Lung Transplant Recipients After Lung Volume Reduction Surgery. Chest, 2004, 126, 1569-1574.	0.4	32
95	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 198-207.	2.5	32
96	Delayed Development of Obliterative Bronchiolitis Syndrome With OKT3 After Unilateral Lung Transplantation. Chest, 1996, 109, 870-873.	0.4	31
97	Supranormal Expiratory Airflow after Bilateral Lung Transplantation Is Associated with Improved Survival. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 79-87.	2.5	31
98	Lung transplantation in <scp>IIP</scp>: A review. Respirology, 2016, 21, 1173-1184.	1.3	31
99	Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome11Note: The opinions and assertions contained herein are the private views of the authors and do not necessarily represent the opinion of the Department of the Navy or of the Department of Defense.. Journal of Heart and Lung Transplantation, 1999, 18, 1024-1026.	0.3	30
100	Utility of Inhaled Pentamidine Prophylaxis in Lung Transplant Recipients. Chest, 1994, 105, 417-420.	0.4	29
101	Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS ONE, 2018, 13, e0194193.	1.1	29
102	Critical Care of the Adult Patient With Cystic Fibrosis. Chest, 2019, 155, 202-214.	0.4	28
103	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	3.0	28
104	Reversal of Idiopathic Pulmonary Arterial Hypertension and Allograft Pneumonectomy After Single Lung Transplantation. Chest, 2006, 130, 214-217.	0.4	27
105	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	1.3	27
106	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals of the American Thoracic Society, 2020, 17, 1620-1628.	1.5	27
107	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) â€“ A subgroup analysis of the ARIES-E clinical trial. Respiratory Medicine, 2016, 117, 254-263.	1.3	26
108	Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). Journal of Heart and Lung Transplantation, 2021, 40, 488-493.	0.3	26

#	Article	IF	Citations
109	Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. Journal of Heart and Lung Transplantation, 2003, 22, 427-432.	0.3	25
110	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. Drug Design, Development and Therapy, 2014, 8, 875.	2.0	25
111	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 712-719.	0.4	24
112	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2022, 161, 448-457.	0.4	24
113	Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease. Chest, 2022, 162, 145-155.	0.4	24
114	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS ONE, 2020, 15, e0229445.	1.1	23
115	Interferon gamma-1b as Therapy for Idiopathic Pulmonary Fibrosis. Respiration, 2004, 71, 77-82.	1.2	22
116	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiology, 2010, 6, 19-35.	0.5	22
117	Pulmonary hypertension due to interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 459-467.	1.2	22
118	Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine, 2016, 11, 40.	0.6	21
119	RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulmonary Medicine, 2018, 18, 42.	0.8	20
120	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.3	20
121	Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. Journal of Heart and Lung Transplantation, 2022, 41, 458-466.	0.3	20
122	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. European Respiratory Journal, 2018, 52, 1800545.	3.1	19
123	FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. European Respiratory Journal, 2020, 55, 1902151.	3.1	19
124	Single vs. bilateral lung transplantation. Current Opinion in Organ Transplantation, 2018, 23, 316-323.	0.8	18
125	Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Advances in Therapy, 2019, 36, 2910-2926.	1.3	18
126	Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease. Respiratory Medicine, 2015, 109, 517-525.	1.3	17

#	Article	IF	Citations
127	A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 1716-1718.	1.5	17
128	Changes in Neutrophilâ€“Lymphocyte or Plateletâ€“Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 1427.	1.0	17
129	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
130	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 170, 106068.	1.3	16
131	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Current Opinion in Pulmonary Medicine, 2021, 27, 396-404.	1.2	16
132	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. Chest, 2017, 151, 204-214.	0.4	15
133	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. Respiratory Medicine, 2017, 122, S10-S13.	1.3	15
134	Multimodal noninvasive prediction of pulmonary hypertension in IPF. Clinical Respiratory Journal, 2019, 13, 567-573.	0.6	15
135	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
136	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine, 2022, 196, 106801.	1.3	15
137	The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. Advances in Therapy, 2022, 39, 3881-3895.	1.3	15
138	Use of Nd:YAG Laser in Endobronchial Kaposi's Sarcoma. Chest, 1990, 98, 1299-1300.	0.4	14
139	Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis. Thorax, 2022, 77, 1237-1242.	2.7	14
140	Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations. Lung, 2012, 190, 573-578.	1.4	13
141	POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. Chest, 2016, 150, 273-275.	0.4	13
142	Contemporary optimized practice in the management of pulmonary sarcoidosis. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661986893.	1.0	13
143	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. Pulmonary Circulation, 2021, 11, 1-7.	0.8	13
144	Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury. Journal of Heart and Lung Transplantation, 2021, 40, 1454-1462.	0.3	13

#	Article	IF	Citations
145	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. Frontiers in Medicine, 2021, 8, 607720.	1.2	13
146	Prognostic value of the 6min walk test in bronchiolitis obliterans syndrome. Respiratory Medicine, 2009, 103, 1816-1821.	1.3	12
147	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096849.	1.0	12
148	Connective tissue disease-associated interstitial lung disease and outcomes after hospitalization: A cohort study. Respiratory Medicine, 2019, 154, 1-5.	1.3	11
149	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
150	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. Open Forum Infectious Diseases, 2021, 8, ofab391.	0.4	11
151	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. Current Respiratory Care Reports, 2012, 1, 233-242.	0.6	10
152	Association Between Anticoagulation and Survival in Interstitial Lung Disease. Chest, 2021, 159, 1507-1516.	0.4	10
153	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respiratory Research, 2021, 22, 5.	1.4	10
154	Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 58, 2004053.	3.1	10
155	Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax, 2023, 78, 368-375.	2.7	10
156	Successful Lung Transplantation From a Donor With a Saddle Pulmonary Embolus. Journal of Heart and Lung Transplantation, 2005, 24, 1137-1139.	0.3	9
157	Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respiratory Medicine, 2015, 109, 1582-1588.	1.3	9
158	Novel management strategies for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 831-842.	1.0	9
159	Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110470.	0.5	9
160	Therapeutic Intervention. Chest, 2005, 128, 533S-539S.	0.4	8
161	Early postoperative management after lung transplantation: Results of an international survey. Clinical Transplantation, 2017, 31, e12985.	0.8	8
162	A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation. Chest, 2018, 153, e53-e56.	0.4	8

#	Article	IF	Citations
163	Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. Pulmonary Circulation, 2021, 11, 1-9.	0.8	8
164	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. European Respiratory Journal, 2016, 47, 1615-1617.	3.1	7
165	Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons. Expert Review of Respiratory Medicine, 2021, 15, 175-181.	1.0	7
166	Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction. American Journal of Transplantation, 2022, 22, 2560-2570.	2.6	7
167	Significance of early bronchoscopic airway abnormalities after lung transplantation. Journal of Heart and Lung Transplantation, 2003, 22, 583-586.	0.3	6
168	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. Respiratory Medicine, 2017, 122, S28-S34.	1.3	6
169	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. European Respiratory Journal, 2018, 52, 1801015.	3.1	6
170	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
171	Hypersensitivity pneumonitis and pulmonary hypertension: how the breeze affects the squeeze. European Respiratory Journal, 2014, 44, 287-288.	3.1	5
172	Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat?. Thorax, 2014, 69, 107-108.	2.7	5
173	Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?. Thorax, 2016, 71, 107-109.	2.7	5
174	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-10.	0.8	5
175	Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia. Journal of Computer Assisted Tomography, 2021, 45, 776-781.	0.5	5
176	Idiopathic Pulmonary Fibrosis in Transplantation. Chest, 2003, 124, 2404-2405.	0.4	4
177	Immunohistochemistry Analysis for Proliferation Marker in IPF Lung Tissue. Chest, 2010, 138, 540A.	0.4	4
178	Does 1-Minute Walk Test Predict Results of 6-Minute Walk Test in Patients With Idiopathic Pulmonary Fibrosis?. Chest, 2017, 152, A486.	0.4	4
179	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1459-1461.	2.5	4
180	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemporary Clinical Trials, 2021, 100, 106227.	0.8	4

#	Article	IF	Citations
181	Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients. journal of applied laboratory medicine, The, 2022, , .	0.6	4
182	Evaluating new treatment options. American Journal of Managed Care, 2017, 23, S183-S190.	0.8	4
183	Spinal Aspergillus Abscess in a Patient with Bronchocentric Granulomatosis. Journal of Intensive Care Medicine, 1995, 10, 45-48.	1.3	3
184	Pulmonary Hypertension due to Fibrotic Lung Disease: Hidden Value in a Neutral Trial. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 131-132.	2.5	3
185	Organ Donors. Chest, 2015, 148, 303-305.	0.4	3
186	A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 975-982.	1.0	3
187	Lung transplantation in China: a firm foundation for a solid future. Annals of Translational Medicine, 2020, 8, 265-265.	0.7	3
188	Orthotopic Lung Transplant for Sarcoidosis. Chest, 2003, 123, 963.	0.4	2
189	Using Pharmacovigilance to Assess the Safety of Interferon Gamma-1b in Patients With Severe		

#	Article	IF	Citations
199	A 48-Year-Old South African Woman with Rheumatoid Arthritis and Lung Nodules. Chest, 2020, 157, e151-e155.	0.4	2
200	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of IPF. Annals of the American Thoracic Society, 2021, 18, 1803-1810.	1.5	2
201	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021005.	0.2	2
202	Lung Diseaseâ€"Related Pulmonary Hypertension. Cardiology Clinics, 2022, 40, 77-88.	0.9	2
203	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021032.	0.2	2
204	Lung transplant candidate selection and clinical outcomes: strategies for improvement in prioritization. Current Opinion in Organ Transplantation, 2005, 10, 216-220.	0.8	1
205	ECHOCARDIOGRAPHY AS A PREDICTOR OF PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. Chest, 2007, 132, 428B.	0.4	1
206	CAT SCAN CORRELATION BETWEEN PULMONARY ARTERY DIAMETER AND PULMONARY ARTERY PRESSURE IN IDIOPATHIC PULMONARY FIBROSIS. Chest, 2007, 132, 582C.	0.4	1
207	Response. Chest, 2014, 145, 1440-1441.	0.4	1
208	Tracheobronchial Tree Size as a Predictor of Disease Severity and Outcomes in Idiopathic Pulmonary Fibrosis. Chest, 2017, 152, A487.	0.4	1
209	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S3-S4.	0.5	1
210	EFFECT OF PIRFENIDONE ON EXERCISE CAPACITY AND DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND MORE ADVANCED LUNG FUNCTION IMPAIRMENT. Chest, 2018, 154, 432A-433A.	0.4	1
211	CATEGORIZATION OF GROUP 3 PULMONARY HYPERTENSION BY THE 2018 DEFINITION: WHO IS IN, WHO IS OUT?. Chest, 2019, 156, A872-A873.	0.4	1
212	OPEN-LABEL DOSE-ESCALATION DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (INO) IN SUBJECTS AT RISK OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS (PH-PF) ON LONG TERM OXYGEN THERAPY. Chest, 2019, 156, A2273-A2275.	0.4	1
213	A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease. Chest, 2020, 157, 1391-1392.	0.4	1
214	INCIDENCE AND RELATED OUTCOMES OF PULMONARY HYPERTENSION IN IDIOPATHIC PULMONARY FIBROSIS. Chest, 2005, 128, 217S.	0.4	1
215	PH in Patients with Lung Disease and Hypoxia. Advances in Pulmonary Hypertension, 2009, 8, 163-171.	0.1	1
216	Mortality from time of listing for transplantation as an indicator of candidate outcomes. Progress in Transplantation, 2004, 14, 29-32.	0.4	1

#	Article	IF	Citations
217	SEVERE THROMBOCYTOPENIA DUE TO IV EPOPROSTENOL: DON'T MUCK WITH THE PLATELETS. Chest, 2021, 160, A2180-A2181.	0.4	1
218	COMPARISON OF EFFECTS OF INHALED TREPROSTINIL ON LUNG FUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION. Chest, 2021, 160, A2244-A2246.	0.4	1
219	Lung nodules due to Candida parapsilosis in a person with cystic fibrosis. BMJ Case Reports, 2021, 14, e245441.	0.2	1
220	Telesupport. Chest, 2002, 122, 1114-1116.	0.4	0
221	Pulmonary Hypertension in Sarcoidosis: Identifying Potential Risk Factors. Chest, 2004, 126, 742S.	0.4	0
222	Distance-Saturation Product as a Marker of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. Chest, 2004, 126, 888S.	0.4	0
223	PULMONARY HYPERTENSION IN PATIENTS WITH BRONCHIOLITIS OBLITERANS POST-LUNG TRANSPLANTATION. Chest, 2007, 132, 596B.	0.4	0
224	PRACTICE PATTERNS REGARDING MANAGING PULMONARY HYPERTENSION IN PATIENTS WITH PARENCHYMAL LUNG DISEASES: RESULTS OF AN ACCP SURVEY. Chest, 2008, 134, 134P.	0.4	0
225	Pulmonary Hypertension in Interstitial Lung Disease Diagnosis and Management. Clinical Pulmonary Medicine, 2009, 16, 252-257.	0.3	0
226	Antifibrotic Effect of Curcumin on Primary Fibroblasts From IPF Lungs. Chest, 2010, 138, 797A.	0.4	0
227	An image analysis method for quantification of idiopathic pulmonary fibrosis. , 2011, , .		0
228	A Multicenter, Retrospective Study of Patients With Pulmonary Arterial Hypertension Who Received Inhaled Iloprost for More Than One Year. Chest, 2011, 140, 743A.	0.4	0
229	Do CT Findings Correlate With the Phenomena of â€œBOSâ€•and â€œDeBOS/ReBOSâ€•in Lung Transplant Patients?. Chest, 2011, 140, 670A.	0.4	0
230	Unilateral Absence of Pulmonary Artery: An Uncommon Cause of Pulmonary Hypertensio. Chest, 2011, 140, 182A.	0.4	0
231	Current Clinical Practices in PAH: Challenges and Opportunities to Improve Care. Chest, 2012, 142, 836A.	0.4	0
232	The Relationship Between Red Cell Distribution Width and Mortality After Lung Transplantation. Chest, 2012, 142, 1095A.	0.4	0
233	Primary Central Nervous System Lymphoma: A Rare Post Lung Transplantation Lymphoproliferative Disorder. Chest, 2012, 142, 1040A.	0.4	0
234	Differentiation of IPF From NSIP by Cytokine Profiling. Chest, 2012, 142, 957A.	0.4	0

#	Article	IF	Citations
235	Six-Minute Walk Test Pulse Rate Recovery as a Predictor of Pulmonary Hypertension and Mortality in COPD. Chest, 2013, 144, 689A.	0.4	0
236	Treatment of Pulmonary Hypertension in COPD: Implications for Exercise Tolerance and Mortality. Chest, 2013, 144, 853A.	0.4	0
237	Predictive Value of Lung Physiology in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 473A.	0.4	0
238	Success of Educational Interventions on Pulmonary Arterial Hypertension Management. Chest, 2013, 144, 859A.	0.4	0
239	Adenovirus Infection Presenting as a Solitary Mass Lesion With Lymphocytic Effusion in a Lung Transplant Recipient. Chest, 2014, 146, 984A.	0.4	0
240	Effect of Pirfenidone on All-Cause Mortality in Patients With Idiopathic Pulmonary Fibrosis (IPF): Comparison of Pooled Analysis With Meta-analysis From the ASCEND and CAPACITY Trials. Chest, 2015, 148, 363A.	0.4	0
241	Lung Mass Associated With Cystic Lung Disease: An Evasive Diagnosis in a Patient With Primary SjÃ¶gren's. Chest, 2015, 148, 853A.	0.4	0
242	Rebuttal From Drs King andÂNathan. Chest, 2016, 150, 278.	0.4	0
243	Tolerability and Efficacy of Selexipag in Real Life Clinical Setting. Chest, 2017, 152, A998.	0.4	0
244	RISING INCIDENCE OF PULMONARY EMBOLISM POST-LUNG TRANSPLANTATION: A SINGLE CENTER EXPERIENCE. Chest, 2018, 154, 1103A-1104A.	0.4	0
245	CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE AND OUTCOMES AFTER HOSPITALIZATION: A COHORT STUDY. Chest, 2018, 154, 418A-419A.	0.4	0
246	COMBINING RADIOLOGY AND ENVISIA, A MOLECULAR CLASSIFIER, TO IMPROVE USUAL INTERSTITIAL PNEUMONIA (UIP) DIAGNOSIS. Chest, 2019, 156, A253-A256.	0.4	0
247	WBC COUNT AS A PROGNOSTIC INDICATOR IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS. Chest, 2019, 156, A1071-A1072.	0.4	0
248	EVALUATING CLINICAL UTILITY OF A UIP GENOMIC CLASSIFIER IN SUBJECTS WITH AND WITHOUT A HRCT PATTERN OF UIP. Chest, 2019, 156, A175-A178.	0.4	0
249	SUCCESSFUL CALCINEURIN-INHIBITOR-FREE IMMUNOSUPPRESSION REGIMEN WITH SIROLIMUS AND PREDNISONE IN LUNG TRANSPLANT RECIPIENTS: A CASE SERIES. Chest, 2020, 158, A2383.	0.4	0
250	HIGHER DONOR PAO2/FIO2 RATIO APPEARS TO BE ASSOCIATED WITH INCREASED INCIDENCE OF PRIMARY GRAFT DYSFUNCTION IN LUNG TRANSPLANT RECIPIENTS. Chest, 2020, 158, A2399-A2400.	0.4	0
251	RELATIONSHIP BETWEEN ENVISIA GENOMIC CLASSIFIER AND AN HRCT-DERIVED FIBROTIC INDEX FROM DATA DRIVEN TEXTURE ANALYSIS ON 50 ILD PATIENTS. Chest, 2020, 158, A1064-A1065.	0.4	0
252	A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION. Chest, 2020, 158, A1878-A1879.	0.4	0

#	Article	IF	Citations
253	DOES SURGICAL LUNG BIOPSY CHANGE MANAGEMENT IN HOSPITALIZED PATIENTS WITH SUSPECTED INTERSTITIAL LUNG DISEASE?. Chest, 2020, 158, A1068-A1069.	0.4	0
254	OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND PULMONARY HYPERTENSION. Chest, 2020, 158, A1071-A1072.	0.4	0
255	Rebuttal From Dr Nathan. Chest, 2020, 157, 1415.	0.4	0
256	Atraumatic forearm swelling in a patient with poorly controlled asthma. Respiratory Medicine Case Reports, 2021, 33, 101454.	0.2	0
257	CHARACTERIZATION OF PATIENTS WITH PULMONARY HYPERTENSION DUE TO COPD: A REAL-WORLD DATA ANALYSIS. Chest, 2021, 160, A1784-A1785.	0.4	0
258	COMPARISON OF IDIOPATHIC VS CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION GROUPS IN US CLINICAL PRACTICE. Chest, 2021, 160, A2301-A2303.	0.4	0
259	SCREENING FOR PULMONARY HYPERTENSION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE: RECOMMENDATIONS FROM A DELPHI CONSENSUS PANEL. Chest, 2021, 160, A1239-A1242.	0.4	0
260	INCIDENCE AND IMPACT OF POST-OPERATIVE ACUTE KIDNEY INJURY REQUIRING RENAL REPLACEMENT THERAPY DURING INDEX LUNG TRANSPLANT HOSPITALIZATION. Chest, 2021, 160, A2500-A2501.	0.4	0
261	TRANSTHORACIC ECHOCARDIOGRAM (ECHO) AND RIGHT HEART CATHETERIZATION (RHC) AS DISEASE MANAGEMENT TOOLS FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) IN US CLINICAL PRACTICE. Chest, 2021, 160, A2331-A2333.	0.4	0
262	DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING. Chest, 2021, 160, A2279-A2280.	0.4	0
263	CARE AND CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) IN US CLINICAL PRACTICE. Chest, 2021, 160, A2287-A2289.	0.4	0
264	THE IMPACT OF HEMODYNAMIC PARAMETERS ON INHALED TREPROSTINIL TREATMENT RESPONSE: A SUBGROUP ANALYSIS FROM THE INCREASE TRIAL. Chest, 2021, 160, A2265-A2266.	0.4	0
265	Correlation of Select Cytokines With Disease Severity in Patients With IPF or NSIP. Chest, 2012, 142, 427A.	0.4	0
266	Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. Journal of Medical Cases, 2019, 10, 260-263.	0.4	0
267	IPF in Saudi Arabia: Lessons for all. Annals of Thoracic Medicine, 2020, 15, 183.	0.7	0
268	Piecing together the bigger picture: Idiopathic pulmonary fibrosis in Australia and beyond. Respirology, 2022, , .	1.3	0
269	Reply to: Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
270	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. , 2020, 15, e0242651.		0

#	Article	IF	Citations
271	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. , 2020, 15, e0242651.		0
272	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. , 2020, 15, e0242651.		0
273	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. , 2020, 15, e0242651.		0